Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

En undersøgelse, der evaluerer NPT 2042 versus placebo hos forsøgspersoner i alderen 16-75 år med genetisk generaliseret epilepsi (GGE) og absenceanfald

24. september 2026 opdateret af: NeuroPro Therapeutics, Inc.

Et enkeltcenter, dobbeltblindt, placebokontrolleret crossover-studie, der evaluerer NPT 2042 versus placebo hos forsøgspersoner i alderen 16-75 år med genetisk generaliseret epilepsi (GGE) og absenceanfald

This study will compare the effect of NPT 2042 and placebo in subjects with GGE on the frequency and duration of electroencephalographic absence seizures, separated by a 14-day washout period. The study will be a single-center, double-blind, crossover study with subjects receiving either NPT 2042 BID orally or matching placebo BID in each of two treatment periods. Two doses of NPT 2042 will be evaluated.

Studieoversigt

Status

Afsluttet

Intervention / Behandling

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

14

Fase

  • Fase 2

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • Arkansas
      • Little Rock, Arkansas, Forenede Stater, 77205
        • Clinical Trials, Inc. (CTI)

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

16 år til 75 år (Barn, Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  1. Subject is capable of and provides consent/assent, and the study participant's parent/legal representative/caregiver provides signed informed consent for minor study participants, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF)
  2. Subject is aged 16-75 years at the time of consent/assent
  3. Subject is diagnosed with genetic generalized epilepsy with absence seizures (consistent with the International League Against Epilepsy (ILAE) Classification of Seizures (2017))
  4. Subject has electroencephalogram (EEG) evidence of bilateral synchronous generalized paroxysmal spike-wave (2.5 Hz to 6 Hz) bursts lasting 3 seconds or more at least 4 times on the screening 72-hour ambulatory EEG.
  5. Subject has been on a stable dose of at least one antiseizure medication (ASM) for at least 30 days. Vagal nerve stimulation at stable settings (for at least 30 days before screening), without use of the magnet, is also acceptable.
  6. Subject has normal cognition and no clinically significant abnormalities on neurological examination at screening in the opinion of the Investigator
  7. Subject is in otherwise good health (with the exception of epilepsy), as determined by the investigator, and as documented in the medical history, physical examination, and screening laboratory investigations
  8. Subject has a body mass index (BMI) between 18 and 40 kg/m2 inclusive, at screening
  9. Female subjects of child-bearing potential and all men agree to use of highly effective methods of contraception during the study and for 28 days after last dose of study drug
  10. Subject (and parent/caregiver, if applicable) is able to communicate with the investigator and to understand and comply with all study requirements, including the clinic visit schedule

Exclusion Criteria:

  1. Subject has metabolic or mitochondrial encephalopathies, seizures associated with structural abnormalities, or infection-related seizures.

  2. Subject has a developmental epileptic encephalopathy (e.g. Lennox-Gastaut syndrome)

  3. Subject has a history of convulsive status epilepticus within the past year.

  4. Subject has a history of surgical intervention for treatment of epilepsy

  5. Subject has a history of nonepileptic seizures (e.g., metabolic, structural, or paroxysmal non epileptic seizures)

  6. Subject has severe intellectual disability, severe autism spectrum disorder, or severe developmental disorder such that the subject cannot consent or assent to participate or cannot cooperate with the study procedures

  7. Female subject who is pregnant or lactating

  8. Subject has any clinically significant laboratory abnormality which, in the opinion of the investigator, will exclude the subject from the study

  9. Subject has an active CNS infection, demyelinating disease, degenerative neurological disease, or any CNS disease deemed to be progressive during the course of the study that may confound the interpretation of the study results

  10. Subject has any clinically significant psychiatric illness, psychological or behavioral problems which, in the opinion of the investigator, would interfere with the subject's ability to participate in the study, including but not limited to the following:

    1. Subject has active suicidal ideation prior to study entry as indicated by a positive response ("yes") to either Question 4 or Question 5 of the Columbia Suicide Severity Rating Scale (C-SSRS)
    2. Study participant has a lifetime history of suicide attempt (including an active attempt, interrupted attempt, or aborted attempt)
  11. Subject is suffering from clinically significant active liver disease, porphyria or has a family history of severe hepatic dysfunction indicated by abnormal liver function tests greater than three times the upper limit of normal (AST and ALT)

  12. Subject has a DSM-V diagnosis of alcohol or drug abuse, or drug addiction within the past 12 months

  13. Subject has participated in any other trials involving an investigational product or device within 30 days of screening or longer, as required by local regulations

  14. Subject is currently using prohibited medications or products

  15. Subject is unable to complete ingestion of four placebo SGCs with a minimum of eight ounces of water at screening

  16. Subject (and parent/caregiver, if applicable) has daily commitments during the study duration that would interfere with attending all study visits

  17. Positive urine drug test for substance of abuse or illegal recreational substances at screening

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Crossover opgave
  • Maskning: Firedobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Aktiv komparator: NPT 2042 80mg

NPT 2042 80mg BID

NPT 2042 is a new drug being developed as an anti-seizure treatment

Placebo Comparator

Placebo komparator: Placebo for NPT 2042 80mg

Matching placebo for active comparator

NPT 2042 is a new drug being developed as an anti-seizure treatment

Placebo Comparator

Aktiv komparator: NPT 2042 160mg

NPT 2042 160mg BID

NPT 2042 is a new drug being developed as an anti-seizure treatment

Placebo Comparator

Placebo komparator: Placebo for NPT 2042 160mg

Matching placebo for active comparator

NPT 2042 is a new drug being developed as an anti-seizure treatment

Placebo Comparator

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Mean and median across subjects of the within subject difference in percent change from treatment period baseline of the frequency of absence seizures
Tidsramme: Up to 12 weeks

Mean and median across subjects of the within subject difference in percent change from treatment period baseline of the frequency of absence seizures (defined as 2.5-6 Hz spike-wave bursts lasting greater than 3 seconds) between NPT 2042 and placebo.

Up to 12 weeks

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Mean and median across subjects of the within subject difference between NPT 2042 and placebo on absence seizures
Tidsramme: Up to 12 weeks

Mean and median across subjects of the within subject difference between NPT 2042 and placebo on absence seizures (defined as 2.5-6 Hz spike-wave bursts lasting greater than 3 seconds) average duration.

Up to 12 weeks
Mean and median across subjects of the within subject categorical difference in percent change between NPT 2042 and placebo of the frequency of absence seizure
Tidsramme: Up to 12 weeks

Mean and median across subjects of the within subject categorical difference in percent change between NPT 2042 and placebo of the frequency of absence seizure (defined as 2.5-6 Hz spike wave bursts lasting greater than 3 seconds) using the following categories:

  • 1 - < 3 seconds
  • 3 - 5 seconds
  • >5 - 10 seconds
  • >10 seconds
Up to 12 weeks
The proportion of NPT 2042- vs. placebo-treated subjects meeting the study specific response criteria
Tidsramme: Up to 12 weeks

The proportion of NPT 2042- vs. placebo-treated subjects meeting the following response criteria:

  • ≥50% decrease in endpoint seizure frequency compared to treatment period baseline
  • ≥75% decrease in endpoint seizure frequency compared to treatment period baseline
  • Seizure freedom
Up to 12 weeks
The mean change from Baseline across subjects of the within subject difference between NPT 2042 and placebo on the Quality of Life in Epilepsy Questionnaire (QOLIE-31-P)
Tidsramme: Up to 12 weeks

The mean change from Baseline across subjects of the within subject difference between NPT 2042 and placebo on the Quality of Life in Epilepsy Questionnaire (QOLIE-31-P)

Up to 12 weeks
The mean change from Baseline in the Digit Symbol Substitution Test
Tidsramme: Up to 12 weeks

The mean change from Baseline in the Digit Symbol Substitution Test following treatment with NPT 2042 compared to placebo

Up to 12 weeks
The mean change from Baseline in the Epworth Sleepiness Scale
Tidsramme: Up to 12 weeks

The mean change from Baseline in the Epworth Sleepiness Scale following treatment with NPT 2042 compared to placebo

Up to 12 weeks

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

11. marts 2025

Primær færdiggørelse (Faktiske)

17. august 2026

Studieafslutning (Faktiske)

23. september 2026

Datoer for studieregistrering

Først indsendt

23. december 2024

Først indsendt, der opfyldte QC-kriterier

7. januar 2025

Først opslået (Faktiske)

10. januar 2025

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

28. september 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

24. september 2026

Sidst verificeret

1. september 2026

Mere information

Begreber relateret til denne undersøgelse

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner